THE MEDICAL NEWS

coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont® Scientific Ltd.

Labconco Corporation is excited to mark its 50th anniversary of biosafety cabinet innovation by adding another BSC to its already comprehensive portfolio.

Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 million) in funding.

Respiratory infections are among the leading causes of illness and death in the elderly, driven by immune aging, chronic diseases, and reduced physiological resilience.

As more Americans receive treatment for opioid use disorder, that progress is increasingly showing up in the operating room, creating an urgent need to modernize how pain is managed during and after major surgery, according to a study in the February 2026 issue of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA).

Today, the ACCESS-AD consortium is announcing the launch of a transformative European initiative that will accelerate the implementation of scientific innovations for Alzheimer's disease (AD) management in real-world health systems.

Most COVID-19 vaccine hesitancy is rooted in concerns that can be addressed and effectively reduced over time, according to a new study following more than 1.1 million people in England between January 2021 and March 2022 during the COVID-19 pandemic, published in The Lancet.

A new study suggests that a little-known region deep in the brain could be crucial for preserving physical strength as we age. The findings could help detect and prevent frailty before it begins.

Pennington Biomedical researchers recently investigated the systems of the body that regulate weight, exploring whether our bodies defend an established weight target or if our bodies operate within a broader range of tolerance before biological mechanisms are activated.

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.